Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
53,244,611
-
Share change
-
+9,909,820
-
Total reported value
-
$133,114,000
-
Put/Call ratio
-
66%
-
Price per share
-
$2.50
-
Number of holders
-
41
-
Value change
-
+$23,326,834
-
Number of buys
-
21
-
Number of sells
-
22
Institutional Holders of CTI BIOPHARMA CORP - COM (CTIC) as of Q2 2021
As of 30 Jun 2021,
CTI BIOPHARMA CORP - COM (CTIC) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,244,611 shares.
The largest 10 holders included
BVF INC/IL, Stonepine Capital Management, LLC, ORBIMED ADVISORS LLC, NEA Management Company, LLC, Altium Capital Management LP, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, CAXTON CORP, Ghost Tree Capital, LLC, and TWO SIGMA INVESTMENTS, LP.
This page lists
41
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.